Resources

  • Statement

    Incubate Statement on Amendment 5284 of the Inflation Reduction Act
    08.06.2022

    Incubate issued the following statement in response to amendment 5284 of the Inflation Reduction Act:

  • Article

    US Government Poised for Long-Awaited Powers on Drug Pricing
    08.06.2022

    Via Bloomberg: Drugmakers have long said R&D will suffer if prices regulated

  • Article

    HEALTH CARE BRIEFING: Senate Drug Measures Cut Deficit, CBO Says
    08.04.2022

    Via Bloomberg Government: Senate Democrats’ tax, climate, and drug-pricing bill would cut down federal budget deficits by $102 billion over 10 years, the nonpartisan Congressional Budget Office said.

  • Article

    Biotech Investors Sound the Alarm on Senate Drug Pricing Bill
    08.03.2022

    Via the Washington Times: A group of biotech investors and doctors are warning that the Senate’s drug-pricing proposal, aimed at lowering skyrocketing prices, would “strike a huge blow” to patient access and halt research on new treatments for Alzheimer’s disease, heart disease and cancer.

  • Article

    Don’t Look Up? Congress Can’t Ignore Risk to Small Molecule Drugs in Pricing Bill, Investors Warn
    08.03.2022

    A budget-neutral fix that would extend the time before small molecule drugs are subject negotiations but increase the minimum discounts for the products is floated as the pricing legislation moves toward a Senate floor vote.

  • Video

    Incubate Investor Panel on the Senate’s Inflation Reduction Act of 2022
    08.03.2022

    Members of Incubate's network, Peter Kolchinsky, PhD, Managing Partner at RA Capital Management; JF Formela, MD, Partner at Atlas Venture; Guarav Gupta, MD, MS - Founder and Managing Partner, Ascendant BioCapital; and Duane Schulthess, Managing Director of Vital Transformation, speak on the impacts of the Inflation Reduction Act on the early-stage life science industry.

  • Statement

    Incubate Letter on Reconciliation Drug Pricing Provisions
    07.15.2022

    Read Incubate's letter to the US Senate on their recent drug price provisions in the Reconciliation package

  • Statement

    Incubate Statement on Federal Drug Price Provisions
    07.06.2022

    See Incubate's statement in response to the recent Reconciliation bill text on drug price controls.

  • Statement

    Incubate Statement on WTO Decision to Suspend Global IP Rights
    06.30.2022

    The Incubate Coalition issued the following statement preceding the WTO TRIPS Council meeting (July 6-7) and following the World Trade Organization’s decision at its 12th Ministerial Conference in Geneva, Switzerland to waive intellectual property (IP) protections for Covid-19 vaccines.

  • Article

    LTE: Patents protect people’s access to life-saving medicine
    06.05.2022

    See Incubate's letter to the editor about why patents are necessary in protecting patient access.

  • Statement

    Incubate Comment in Response to the FTC’s Request for Comments on the Business Practices of PBMs
    05.25.2022

    Read Incubate's response to the FTC's Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers 

  • Statement

    Incubate Executive Director John Stanford Statement in Response to the Centers for Medicare & Medicaid Services’ Devastating Final National Coverage Determination for Certain Alzheimer’s Treatments
    04.14.2022

    See Executive Director John Stanford's statement on CMS' Final NCD on Alzheimer's disease and how this will affect the future of biopharmaceutical investment.